CeriBell, Inc. (NASDAQ:CBLL) Receives Consensus Rating of "Buy" from Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) have been given an average rating of "Buy" by the eight analysts that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have covered the stock in the last year is $32.14.

A number of research analysts recently commented on the company. BTIG Research began coverage on CeriBell in a research report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 price target on the stock. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price on the stock.

Insiders Place Their Bets

In other news, Director Rebecca B. Robertson sold 11,188 shares of CeriBell stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total transaction of $199,705.80. Following the sale, the director directly owned 10,042 shares of the company's stock, valued at approximately $179,249.70. This trade represents a 52.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Xingjuan Chao sold 25,000 shares of the business's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $17.70, for a total value of $442,500.00. Following the sale, the chief executive officer owned 776,022 shares in the company, valued at approximately $13,735,589.40. This trade represents a 3.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 138,333 shares of company stock worth $2,337,695. Insiders own 20.10% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CBLL. Ameriprise Financial Inc. acquired a new position in CeriBell in the 4th quarter valued at approximately $368,000. Corebridge Financial Inc. acquired a new stake in CeriBell in the fourth quarter valued at $158,000. PNC Financial Services Group Inc. bought a new position in CeriBell during the 4th quarter worth $47,000. Bank of America Corp DE acquired a new position in CeriBell during the 4th quarter worth about $498,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in CeriBell during the 4th quarter worth about $10,750,000.

CeriBell Stock Performance

Shares of CBLL traded up $0.07 during mid-day trading on Friday, hitting $15.80. 283,154 shares of the company's stock were exchanged, compared to its average volume of 285,553. The company has a quick ratio of 16.81, a current ratio of 17.36 and a debt-to-equity ratio of 0.11. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75. The stock's 50-day simple moving average is $17.52 and its 200-day simple moving average is $19.50.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. Research analysts predict that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.